Ignite Creation Date:
2024-05-06 @ 7:56 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06194448
Status:
RECRUITING
Last Update Posted:
2024-07-12
First Post:
2023-12-20
Brief Title:
To Evaluate the EfficacySafety of Osimertinib Prior to CRT and Maintenance of it With Stage III Unresectable NSCLC With EGFR Mutations
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-04-21
Start Date Type:
ACTUAL
Primary Completion Date:
2027-04-28
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-03-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-12-20
First Submit QC Date:
January 5 2024
Study First Post Date:
2024-01-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-22
Last Update Post Date:
2024-07-12
Last Update Post Date Type:
ACTUAL